Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.81 |
| ▸ | CTSL | P07711 | 8/20 | 0.81 |
| ▸ | CTSK | P43235 | 9/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306549 | 0.89 | CTSS (1.00) | CTSSCTSLCTSK | |
| SCHEMBL4137993 | 0.89 | CTSS (0.82) | CTSSCTSLCTSK | |
| SCHEMBL5262550 | 0.82 | CTSS (0.69) | CTSSCTSLCTSK | |
| SCHEMBL4269451 | 0.81 | CTSS (0.67) | CTSSCTSLCTSK | |
| SCHEMBL5260821 | 0.81 | CTSS (0.67) | CTSSCTSLCTSK | |
| SCHEMBL13924831 | 0.80 | CTSS (0.85) | CTSSCTSLCTSK | |
| SCHEMBL5260228 | 0.80 | CTSS (0.66) | CTSSCTSLCTSK | |
| SCHEMBL5255878 | 0.79 | CTSS (0.66) | CTSSCTSLCTSK | |
| SCHEMBL13924835 | 0.79 | CTSS (1.00) | CTSSCTSLCTSK | |
| SCHEMBL4136793 | 0.78 | CTSS (0.82) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | CTSS 2927/4885CTSL 3093/4885CTSK 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.